About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Targeted Treatment can Delay Heart Damage Caused by Pancreatic Cancer

by Rishika Gupta on December 1, 2017 at 11:10 AM
Font : A-A+

Targeted Treatment can Delay Heart Damage Caused by Pancreatic Cancer

New target treatment called rapalog can help hormone secreting pancreatic cancer patients, by preventing the cancer spread and protecting heart damage caused by the disease found a new study published in Molecular Cancer Therapeutics journal.

Higher levels of serotonin among other tumor secretions can cause injury to the valves of the heart over time, leading to cardiac impairment, a condition referred to as cardiac carcinoid disease, in these patients.

Advertisement


These findings, reported in the November 2017 issue of Molecular Cancer Therapeutics, could lead to another targeted treatment for patients and prevent the onset of additional complications from their cancer.

"Pancreatic neuro endocrine tumors, pancreatic NETs, pNETs or islet cell tumors, are tumors that form from the abnormal growth of neuroendocrine cells in the pancreas," says lead author Hala Elnakat Thomas, PhD, research assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, and member of the Cincinnati Cancer Consortium and UC Cancer Institute's Pancreatic Cancer Center.
Advertisement

"Most pancreatic NETs are functional, meaning they produce hormones. The overproduction of certain hormones results in a number of symptoms termed carcinoid disease which may impact the patients' quality of life if not managed appropriately."

She says mutations in key players of the mTOR pathway, a molecular pathway present and active in several types of cancer, have been identified in pNETs.

"Inhibiting mTOR signaling using everolimus, a targeted therapy, known as a rapalog, for patients with lung and gastro-entero-pancreatic NETs, has been approved by the FDA. A rapalog inhibits the mTOR protein by preventing it from activating some signals," she says.

"However, patients eventually experience progression of cancer on this treatment, highlighting the need for additional therapies. In this study, we focused on pancreatic NETs (pNETs) and thought that treatment of these tumors upon progression on rapalog therapy, with an mTOR kinase inhibitor (mTORKi), could overcome a number of resistance mechanisms in tumors and delay cardiac carcinoid disease."

Elnakat Thomas' team and colleagues including Jack Rubinstein, MD, a member of the Heart, Lung and Vascular Institute and an associate professor within the UC College of Medicine, performed preclinical studies using human pNET cells injected into animal models to determine tumor progression and cardiac function in those treated with a rapalog alone or switched to the mTORKi (CC-223) when cancer progression was noticed.

"Our results showed that in the majority of pNETs that progress on rapalog therapy, it is possible to reduce disease progression when switching instead to an mTORKi, such as CC-223," Elnakat Thomas says.

"The mTORKi also may lead to additional cardiac benefit by decreasing valvular fibrosis (damage) when compared with placebo or just the rapalog. The mTORKi also inhibit mTOR but they do it differently than rapalogs, and they are stronger inhibitors of signals, so the inhibition is more complete with an mTORKi than a rapalog".

"This data warrants further testing of the long-term cardio-protective benefit of an mTORKi in neuro endocrine tumor patients prone to carcinoid syndrome. Altogether, these results are timely as an mTORKi therapy called sapanisertib is currently in phase II clinical trial testing in pNET patients with metastatic cancer or tumors that are not reacting to treatment and cannot be surgically removed."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Pancreatic Cancer Cancer and Homeopathy Cancer Facts Heart Cancer Tattoos A Body Art Healthy Heart Pancreatitis Statins Mitral Valve Prolapse 

Recommended Reading
An Electronic Nose to Detect Pancreatic Cancer
An electronic nose could be an efficient screening method for the diagnosis of pancreatic cancer, .....
Pancreatic Cancer Survival Depends on Four Genes
Adenocarcinoma is the most common type of pancreas tumor and the chances of a patient's survival ......
New Compound may Help Kill Pancreatic Cancer Stem Cells
The almost uniform and threatening lethality of pancreatic cancer originates in its stem cells. ......
Potential Therapies For Pancreatic Cancer Found
A protein-cleaving enzyme called FAP, for fibroblast activation protein is responsible for ......
Mitral Valve Prolapse
Mitral Valve Prolapse is a relatively common condition and causes leakage of blood through the valve...
Pancreatic Cancer
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. ...
Pancreatitis
Pancreatitis or inflammation of the pancreas may show up as acute pancreatitis or chronic pain. Alco...
Statins
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms bu...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use